Results 61 to 70 of about 8,158 (292)
Equine Veterinary Journal, EarlyView.Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom +3 more
wiley +1 more source
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
, 2013 We report the discovery and translational therapeutic efficacy of a peptide with potent, balanced co-agonism at both of the receptors for the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Hofmann, S. +32 more
core +2 more sources
A New Vista of Opportunity in Diabetes Management: Natural Product‐Based β‐cell Preservation
Food Chemistry International, EarlyView.Preserving functional β‐cells via natural products offers promising strategy for diabetes treatment. ABSTRACT A defining characteristic of diabetes is β‐cell failure, in which β‐cells cannot modulate insulin secretion to compensate for escalating insulin resistance, pushing forward disease development.
Yi‐San Lee +4 more
wiley +1 more source
Frontiers in Microbiology, 2018 Dietary inclusion of resistant starches can promote host health through modulation of the gastrointestinal microbiota, short-chain fatty acid (SCFA) profiles, and lipid metabolism. This study investigated the impact of a transglycosylated cornstarch (TGS)
Monica A. Newman +4 more
doaj +1 more source
Food Safety and Health, EarlyView.Psidium guajava leaves contain potent bioactive compounds like quercetin, myricetin, and triterpenoids that show antioxidant, antidiabetic, anti‐inflammatory, and anticancer effects. They act by modulating NF‐κB, PPARγ, and α‐glucosidase and by inducing apoptosis and cell cycle arrest.
Muhammad Waqar +10 more
wiley +1 more source
The entero-insular axis in type 2 diabetes - incretins as therapeutic agents
, 2001 The search for intestinal factors regulating the endocrine secretion of the pancreas started soon after the discovery of secretin, i.e. nearly 100 years ago.
Creutzfeldt, W., W. Creutzfeldt
core +1 more source
Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects [PDF]
, 2019 AimIncretins [dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide 1 RA (GLP-1 RA)] and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) groups are now routinely used for type 2 diabetes therapy and comprise a large number of medicinal
Manoela Manova +9 more
core +1 more source
Food Safety and Health, EarlyView.Circadian rhythm disruption impairs metabolic regulation, appetite control, and vascular function, promoting obesity and cardiovascular diseases. Evidence highlights a bidirectional relationship where metabolic disorders further disturb circadian timing.
Ghizal Fatima +4 more
wiley +1 more source
Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
, 2013 An important role in the regulation of glucose homeostasis is played by incretins, which are gut-derived hormones released in response to nutrient ingestion.
Opinto G +2 more
core +1 more source
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
, 2023 In the last few decades, glucagon-like peptide-1 receptor (GLP-1R) agonists have changed current guidelines and improved outcomes for individuals with type 2 diabetes.
Andreasen, Christine R. +5 more
core +1 more source